“In India, approximately 74,000 women die from cervical cancer every year, accounting for 1/3rd of the burden of cervical cancer deaths globally. Less than 10,000 pathologists must service a population of 1.3 billion people…Aindra Systems, a tech start-up from India, has developed an innovative workaround. Leveraging artificial intelligence (AI) to provide point-of-care cervical cancer detection, Aindra is demonstrating how strategic use of automated technologies has the potential to democratize access to quality care in low and middle-income countries (LMICs)…
Aindra’s end-to-end diagnostic platform was developed using human-centered design, an iterative approach to design to ensure a final product that meets the needs and circumstances of end-users. Biological samples are stained by an autostainer, converted into a digital image, then analyzed by AI algorithms to differentiate between cancerous cells and healthy cells. This three-part process is done onsite at a clinic, eliminating the need for the tedious process of manual staining and the transport of large batches of samples to distant laboratories. As a result, a patient is told if they have cancerous lesions within 1-2 hours instead of 5-6 weeks.”
If you want to read our other published material, please visit https://marcellus.in/blog/
Note: The above material is neither investment research, nor financial advice. Marcellus does not seek payment for or business from this publication in any shape or form. The information provided is intended for educational purposes only. Marcellus Investment Managers is regulated by the Securities and Exchange Board of India (SEBI) and is also an FME (Non-Retail) with the International Financial Services Centres Authority (IFSCA) as a provider of Portfolio Management Services. Additionally, Marcellus is also registered with US Securities and Exchange Commission (“US SEC”) as an Investment Advisor.
